Loteprednol etabonate/tobramycin

Drug Profile

Loteprednol etabonate/tobramycin

Alternative Names: LE-T; LE-Tobramycin; Loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension; Tobramycin/loteprednol etabonate; Zylet

Latest Information Update: 22 May 2014

Price : $50

At a glance

  • Originator Pharmos Corporation
  • Class Aminoglycosides; Androstadienes; Eye disorder therapies
  • Mechanism of Action Glucocorticoid receptor agonists; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Ocular inflammation

Most Recent Events

  • 05 Aug 2013 Bausch & Lomb has been acquired by Valeant Pharmaceuticals International
  • 27 Oct 2007 Bausch and Lomb has been acquired by Warburg Pincus
  • 27 Jan 2005 Launched for Ocular inflammation in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top